ChroMedX Engages Dr. Hai Shiene Chen as Asia Business Development Advisor

Toronto, Ontario
November 11, 2014

ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: MNLIF, Frankfurt: EIY2),  is pleased to announce the engagement of Dr. Hai Shiene Chen of ACGT Corporation of Toronto, Ontario  to assist the Company in the international commercialization of its innovative point of care and in-vitro diagnostics technologies in the Asian market.
Dr. Chen will assist the Company by pursuing development/commercialization opportunities for the Company’s blood analysis technologies in the Asian market by forging strategic relationships with global healthcare industry leaders and distributors.
”We are very pleased to have Dr. Chen join the ChroMedX team.  His in-depth knowledge of the Point of Care industry and particularly the Chinese market will be a great addition to our commercialization efforts. We expect Dr. Chen’s background and experience will be of great assistance in the Company’s efforts to explore commercialization opportunities in hard to reach markets abroad”, said Dr. Wayne Maddever, ChroMedX CEO
"Business in the life sciences and healthcare sector in China is growing increasingly robust," said Dr. Chen, ACGT's President and CEO. "ACGT understands the challenges of navigating the route for the Chinese marketplace.  With China expected to move to a new phase as the world's largest market within this decade, we have relationships with the right partners to help capitalize on the many opportunities in China now and into the future."
Dr. Hai Shiene Chen, was educated at The Second Military Medical University, Shanghai, China. He received his Medical Degree in 1983, graduating in the top 2% of his class. Between 1986 and 1988, Dr. Chen trained at Harvard Medical School in the field of cancer research. In 1990, Dr. Chen obtained a M. Sc. Degree from the University of Toronto, and while there, directed a research project on HIV. From 1991 to 1996, Dr. Chen was a Managing Director for the Canadian Genetic Diseases Network’s Core Facility. In 1995, Dr. Chen founded ACGT Corporation.
ACGT is a privately owned provider of oligonucleotide synthesis and DNA sequencing services to customers in the Greater Toronto Area and across Canada.  ACGT is considered to be one of the prominent Canadian providers of DNA services. ACGT has consistently been selected as the primary service supplier with superior quality control and fast delivery time for many well-known medical institutions.  More information can be found on the Company’s website:
About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued US and pending international patents, dealing with blood collection, analysis and plasma/serum processing.
Follow ChroMedX Corp.:
Wayne Maddever
President, CEO & Director
W. Clark Kent
Corporate Development
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements such as references to the Company's de-listing from the TSXV, listing on the CNSX, cancellation of current stock options of the Company, completion of the Private Placement, and completion of the transfer of the assets of the patents and patents pending of ChroMedX Inc. are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipa ted in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the TSXV and the CNSX. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at